These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31780034)

  • 1. Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial.
    Li J; Gao Z; Zhang L; Li S; Yang Q; Shang Q; Gao X; Qu H; Gao J; Shi L; Liu Y; Du J; Xu H; Shi D
    Complement Ther Med; 2019 Dec; 47():102209. PubMed ID: 31780034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial.
    Li S; Guo M; Mao H; Gao Z; Xu H; Shi D
    Trials; 2016 Sep; 17(1):451. PubMed ID: 27628038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese herbal compound preparation Qing-Xin-Jie-Yu granules for intermediate coronary lesions in patients with stable coronary artery disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Chen L; Dai L; Xu J; Duan L; Hou X; Zhang L; Song L; Zhao F; Jiang Y
    PLoS One; 2024; 19(7):e0307074. PubMed ID: 39012918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Yugengtongyu Granules in Patients with Stable Coronary Artery Disease on Reducing Adverse Cardiovascular Events: A Double-Blind Controlled Trial.
    Wang D; Li C; Xu X; Xu H; Guo C; Wang J; Guo J; Huang L
    J Altern Complement Med; 2021 Feb; 27(2):142-149. PubMed ID: 33259734
    [No Abstract]   [Full Text] [Related]  

  • 5. Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial.
    Guo M; Wang P; Du J; Fu C; Yang Q; Gao Z; Zhu M; Lv S; Deng Y; Li T; Shi D; Working Group FTX
    Pharmacol Res; 2020 Aug; 158():104883. PubMed ID: 32446979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Taoren Honghua Jian granule in patients with stable coronary artery disease.
    Wang Y; Zhang Y; Du Y; Yang Y; Wei J; Zhang N; Mao M; Du W; Liu P
    Medicine (Baltimore); 2019 Nov; 98(44):e17753. PubMed ID: 31689832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial.
    Wang Y; Wang X; Wang J; Li B; Yu R; Hu Y; Li X; Peng G; Zhang M; Zhu M
    Trials; 2020 Mar; 21(1):287. PubMed ID: 32197640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention.
    Zhang DW; Wang SL; Wang PL; Du JP; Gao ZY; Wang CL; Xu H; Shi DZ
    J Ethnopharmacol; 2020 Feb; 248():112354. PubMed ID: 31689480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qing-Xin-Jie-Yu Granule alleviates atherosclerosis by reshaping gut microbiota and metabolic homeostasis of ApoE-/- mice.
    Wang A; Guan B; Shao C; Zhao L; Li Q; Hao H; Gao Z; Chen K; Hou Y; Xu H
    Phytomedicine; 2022 Aug; 103():154220. PubMed ID: 35675748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qing-Xin-Jie-Yu Granule inhibits ferroptosis and stabilizes atherosclerotic plaques by regulating the GPX4/xCT signaling pathway.
    Zhang J; Wang X; Guan B; Wang X; An X; Wang T; Chen X; Zhao L; Jia J; Song L; Ma D; Li Q; Zhang H; Ju J; Xu H
    J Ethnopharmacol; 2023 Jan; 301():115852. PubMed ID: 36272494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes: A Randomized, Double-blind, Multicenter Clinical Trial.
    Wang X; Hu D; Dang S; Huang H; Huang CX; Yuan MJ; Tang YH; Zheng QS; Yin F; Zhang S; Zhang BL; Gao RL;
    Chin Med J (Engl); 2017 Jul; 130(14):1639-1647. PubMed ID: 28685712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.
    Ge JB; Fan WH; Zhou JM; Shi HM; Ji FS; Wu Y; Zhao YL; Qian J; Jin YZ; Liu YW; Wang SH; He SH; Yang P; Wu J; Lu F; Hou ZS
    Chin Med J (Engl); 2021 Jan; 134(2):185-192. PubMed ID: 33273369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
    Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
    JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Qixue Tongzhi Granule in improving the exercise capacity of stable coronary artery disease: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
    Chao T; Sun J; Huan N; Ge Y; Wang C
    Front Cardiovasc Med; 2023; 10():1186018. PubMed ID: 37663413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).
    Boden WE; O'Rourke RA; Teo KK; Maron DJ; Hartigan PM; Sedlis SP; Dada M; Labedi M; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    Am J Cardiol; 2009 Jul; 104(1):1-4. PubMed ID: 19576311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
    Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
    Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study.
    Zheng Y; Cai GY; He LQ; Lin HL; Cheng XH; Wang NS; Jian GH; Liu XS; Liu YN; Ni ZH; Fang JA; Ding HL; Guo W; He YN; Wang LH; Wang YP; Yang HT; Ye ZM; Yu RH; Zhao LJ; Zhou WH; Li WG; Mao HJ; Zhan YL; Hu Z; Yao C; Wei RB; Chen XM
    Chin Med J (Engl); 2017 Oct; 130(20):2402-2409. PubMed ID: 29052559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.